Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Stock Information for Apollomics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Apollomics Inc.

Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Apollomics Announces Presentation at the 2024 BIO International Convention

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.